Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: The case for a prospective trial [1]

Annals of Oncology

Volumn 19, Issue 2, 2008, Pages 395-396

  Mathew, P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ANAMNESIS; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; HORMONE SUBSTITUTION; HUMAN; LETTER; LYMPHADENOPATHY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RADIOGRAPHY;

EID: 38849121261     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm568     Document Type: Letter

References (5)

1. Huggins C, Hodges CV. The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
2. Pearson OH. Discussion of Dr Huggins' paper "control of cancers of man by endocrinological methods". Cancer Res 1957; 17: 473-479.
3. Soto AM, Sonnenschein C. The two faces of Janus: Sex steroids as mediators of both cell proliferation and cell death. J Natl Cancer Inst 2001; 93: 1673-1675.
4. Kokontis JM, Hay M, Liao S. Progression of LNCaP cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and a role for p27kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998; 12: 941-953.
5. Chuu CP, Hiipakka RA, Fukuchi J et al. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 2005; 65: 2082-2084.